Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling
BY Shorning, MS Dass, MJ Smalley… - International journal of …, 2020 - mdpi.com
Oncogenic activation of the phosphatidylinositol-3-kinase (PI3K), protein kinase B
(PKB/AKT), and mammalian target of rapamycin (mTOR) pathway is a frequent event in …
(PKB/AKT), and mammalian target of rapamycin (mTOR) pathway is a frequent event in …
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
Background Co-inhibition of poly (ADP-ribose) polymerase (PARP) and androgen receptor
activity might result in antitumour efficacy irrespective of alterations in DNA damage repair …
activity might result in antitumour efficacy irrespective of alterations in DNA damage repair …
The genomic landscape of pediatric acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Here, using
whole-genome, exome and transcriptome sequencing of 2,754 childhood patients with ALL …
whole-genome, exome and transcriptome sequencing of 2,754 childhood patients with ALL …
[HTML][HTML] Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
Metastatic progression is the main cause of death in cancer patients, whereas the
underlying genomic mechanisms driving metastasis remain largely unknown. Here, we …
underlying genomic mechanisms driving metastasis remain largely unknown. Here, we …
Biologically informed deep neural network for prostate cancer discovery
The determination of molecular features that mediate clinically aggressive phenotypes in
prostate cancer remains a major biological and clinical challenge,. Recent advances in …
prostate cancer remains a major biological and clinical challenge,. Recent advances in …
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase …
Background Metastatic castration-resistant prostate cancer is enriched in DNA damage
response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the …
response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the …
Genomic correlates of clinical outcome in advanced prostate cancer
Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent
through several comprehensive profiling efforts, but little is known about the impact of this …
through several comprehensive profiling efforts, but little is known about the impact of this …
[HTML][HTML] A decade of clinical development of PARP inhibitors in perspective
Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair
capacities in tumour cells. DNA damage repair defects are common in different cancer types; …
capacities in tumour cells. DNA damage repair defects are common in different cancer types; …
METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer
R García-Vílchez, AM Añazco-Guenkova, S Dietmann… - Molecular cancer, 2023 - Springer
Newly growing evidence highlights the essential role that epitranscriptomic marks play in the
development of many cancers; however, little is known about the role and implications of …
development of many cancers; however, little is known about the role and implications of …